Potent and selective GSK-3β inhibitor (IC50 values are 34 and 304 nM in the presence of 10 and 100 μM ATP respectively).
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 286.28. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.49 mL||17.47 mL||34.93 mL|
|5 mM||0.7 mL||3.49 mL||6.99 mL|
|10 mM||0.35 mL||1.75 mL||3.49 mL|
|50 mM||0.07 mL||0.35 mL||0.7 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Zhong et al (2009) Characterization and development of novel small-molecules inhibiting GSK3 and activating wnt signaling. Mol.Biosyst. 5 1356 PMID: 19823752
Zou et al (2010) Benzo[e]isoindole-1,3-diones as potential inhibitors of glycogen synthase kinase-3 (GSK-3). Synthesis, kinase inhibitory activity, zebrafish phenotype, and modeling of binding mode. J.Med.Chem. 53 994 PMID: 20030405
If you know of a relevant reference for 3F8, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: 3F8, supplier, glycogen, synthase, kinase, gsk-3, inhibitors, inhibits, Glycogen, Synthase, Kinase, 3, Tocris Bioscience
Citations for 3F8
Citations are publications that use Tocris products.
Currently there are no citations for 3F8. Do you know of a great paper that uses 3F8 from Tocris? If so please let us know.
Literature in this Area
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.